Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Melphalan

Interferons

Interferon-alpha

Administration of interferon alpha as a maintenance treatment following autologous stem cell transplantation

Maintenance treatment with pegylated interferon following autologous stem cell transplantation

Allogeneic stem cell transplantation from an HLA identical related or unrelated donor

Second cycle of high-dose melphalan in subjects without an HLA-identical donor

allogeneic stem cell transplant

Hermann Einsele, M.D.

Stefan Knop, M.D.

Werner Linkesch, MD

Johannes Drach, MD

Orhan Sezer, MD

Orhan Sezer, M.D.

Monika Engelhardt, M.D.

Hans H Wolf, M.D.

Dietrich Peest, M.D.

Michael Pfreundschuh, M.D.

Martin Kropff, MD

Christian Straka, MD

Hannes Wandt, M.D.

Bernd, Metzner

Hans G Mergenthaler, M.D.

Katja Weisel, M.D.

Peter Liebisch, MD

Norbert Frickhofen, M.D.

Hermann Einsele, MD

Volker Kunzmann, MD

Stefan Knop, MD

The study is evaluating whether risk-stratification by the means of a chromosomal aberration provides a tool to discriminate between standard and high risk. Risk-adapted therapy is based on allogeneic stem-cell transplantation for high-risk subjects instead of a second autograft in patients with deletion of chromosome 13 who have an HLA-identical stem cell donor available.

The DSMM V protocol is to compare a consolidation treatment for standard-risk patients not displaying del(13) at initial diagnosis following two cycles of high-dose melphalan 200 mg/m² each supported by autologous stem cell retransfusion with interferon versus PEG-interferon. Patients with del(13) are screened for availability of a fully HLA-matched related or unrelated donor. If patient's informed consent is obtained additionally, he is scheduled to undergo an allogeneic SCT following the first cycle of high-dose melphalan. All other subjects are to proceed to a second course of high-dose melphalan similar to the standard-risk group. Initial cytoreduction is foreseen with four cycles of anthracycline-dexamethasone combination followed by combination therapy with ifosfamide/epirubicine/etoposide for stem-cell collection.

Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years

Multizentrische Therapiestudie Des Multiplen Myeloms DSMM V Therapieoptimierungs-Studie Der Deutschen Studiengruppe Multiples Myelom für Patienten Bis 60 Jahre im Stadium II/III

University of Wuerzburg

Spots Global Cancer Trial Database for primary treatment